Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 11, 2009, Pages 1247-1251

  Yilmaz, Yusuf ^a   Ulukaya, Engin ^b   Atug, Ozlen ^a   Dolar, Enver ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Angiopoietin like protein 3; Biomarkers; Liver injury; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; INSULIN; LIVER PROTEIN; REGULATOR PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; ANGIOPOIETINS; BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED;

EID: 70350142150     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832b77ae     Document Type: Article

References (21)

1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115:141-150
2. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14:185-192
3. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91:1125-1149
4. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008; 18:6-14
5. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005; 11:473-479
6. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 2002; 30:151-157
7. Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun 2003; 301:604-609
8. Stejskal D, Karp?́sek M, Humenanská V, Solichová P, Stejskal P. Angiopoietin-like protein 3: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys 2007; 26:230-233 (Pubitemid 350186535)
9. Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000; 346:603-610
10. Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem 2003; 278:21344-21351
11. Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002; 277:33742-33748
12. Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol 2007; 27:366-372
13. Moon HD, Nakajima K, Kamiyama K, Takanashi K, Sakurabayashi I, Nagamine T. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects. Clin Chim Acta 2008; 398:99-104
14. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321
15. Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun 2004; 317:1075-1079
16. Shimamura M, Matsuda M, Ando Y, Koishi R, Yasumo H, Furukawa H, et al. Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. Biochem Biophys Res Commun 2004; 322:1080-1085
17. Wang B,Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455:479-492 (Pubitemid 47624196)
18. Li C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr Opin Lipidol 2006; 17:152-156
19. Li C. A tale of two angiopoietin-like proteins. Curr Opin Lipidol 2007; 18:597-599
20. Ge H, Cha JY, Gopal H, Harp C, Yu X, Repa JJ, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 2005; 46:1484-1490
21. Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, et al. The angiopoietinlike proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem 2009; 28:1419-1424